<PAGE>



                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

/x/ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended December 31, 1998

                                       OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to __________________

             Commission File Number 0-6516

                     DATASCOPE CORP.
------------------------------------------------------
(Exact name of registrant as specified in its charter)

Delaware                                                        13-2529596
--------------------------------------------------------------------------------
(State of other jurisdiction of             (I.R.S. Employer
incorporation or organization)              Identification No.)

       14 Philips Parkway, Montvale, New Jersey  07645-9998
---------------------------------------------------------------------
(Address of principal executive offices)        (Zip Code)

Registrant's telephone number, including area code  (201) 391-8100

--------------------------------------------------------------------------------
Former name, former address and former fiscal year, if changed since last 
report:

         Indicate by check mark whether the registrant 
         (1)   has filed all reports required to be filed by Section 13 or
               15 (d) of the Securities Exchange Act of 1934 during the
               preceding 12 months (or for such shorter period that the
               registrant was required to file such reports), and

         (2)   has been subject to such filing requirements for the past 90
               days.

                               YES  X      NO
                                   ---         -----

Number of Shares of Company's Common Stock outstanding as of January 29, 1999:
15,176,196.


<PAGE>



                        Datascope Corp. and Subsidiaries
                     Management's Discussion and Analysis of
                  Results of Operations and Financial Condition

Results of Operations

      Second quarter and first six months of fiscal 1999 compared to the
      corresponding periods last year.

      Net Sales

         Net sales of $66.7 million in the second quarter and $122.4 million in
         the first six months of fiscal 1999 increased 6% and 5%, respectively.

         Sales of VasoSeal(R) increased 44% and 37% in the second quarter and
         first six months of fiscal 1999, respectively. VasoSeal's dynamic
         growth reflects increasing productivity of the recently expanded direct
         sales organization in the U.S., continued strong market growth, and
         expansion of the Company's international distributor network.

         The Company recently announced receipt of FDA approval to market
         VasoSeal(R) ES, its second generation arterial puncture sealing device,
         and is planning its U.S. market launch within the next several months.
         VasoSeal ES retains the proprietary, extravascular technology of the
         original VasoSeal but features a one-size-fits-all design that
         eliminates the need to measure skin-to-artery distance and the
         hospital's need to stock more than one size device. VasoSeal ES also
         becomes the first vascular sealing device to be approved for use on
         patients with peripheral vascular disease (PVD), a significant portion
         of the total patient population. The Company believes that its
         competitive position will further strengthen with the introduction of
         the VasoSeal ES product.

         Sales of new patient monitoring products, including the Expert(TM),
         Accutorr(R) and MRI monitors, rose sharply in the second quarter of
         fiscal 1999. Total sales were only slightly ahead of last year,
         however, because sales of Passport monitors in the second quarter last
         year included several large shipments that did not recur. In the first
         six months of fiscal 1999, sales growth of patient monitoring products
         was modest because the Company's supplier could not produce enough new
         anesthetic gas modules (AGM) to support the market launch of the new
         Expert. The outside supplier of the AGM corrected its production
         problem and the supply of AGMs caught up to market demand in the second
         quarter. The Company anticipates increased sales growth for patient
         monitoring products for the balance of the year.


<PAGE>



         The Cardiac Assist Division strengthened its market leadership in the
         U.S. as a result of excellent customer response to its two major new
         products: the System 98 balloon pump and the Profile 8 Fr. balloon
         catheter. During the second quarter, U.S. sales increased 11%, the
         first double-digit quarterly increase since fiscal 1995. Higher sales
         in European direct selling markets were offset by lower pump sales to
         the Company's international distributors, thus worldwide cardiac assist
         sales increased modestly during the second quarter and first six months
         of fiscal 1999. The Company expects stronger gains in the second half
         of fiscal 1999.

         Sales of InterVascular, Inc. increased in the second quarter as a
         result of higher sales of the InterGard(R) collagen coated graft in
         Europe, including a new heparin- coated graft which received the CE
         mark in the first quarter. Sales of vascular grafts in the first six
         months of fiscal 1999 declined from the same period last year due to
         pipeline filling shipments of the InterGard collagen coated grafts to
         the Company's distributors in the U.S. and Japan in the first quarter
         of fiscal 1998. The Company plans to introduce a range of antimicrobial
         grafts in the second half of fiscal 1999, pending receipt of the CE
         mark, and expects increasing sales for the balance of the year.

         The weaker U.S. dollar compared to major European currencies increased
         total sales by approximately $300 thousand in the second quarter and
         first six months of fiscal 1999.

      Gross Profit (Net Sales Less Cost of Sales)

         The gross profit percentage was 65.2% and 65.4% for the second quarter
         and first six months of fiscal 1999, respectively, compared to 64.2%
         and 64.3% for the corresponding periods last year with the improvement
         primarily attributable to a favorable mix of sales, higher selling
         prices for the VasoSeal device and cost reductions in the Patient
         Monitoring and Collagen Products divisions, and InterVascular, Inc.
         Partially offsetting the above were costs associated with the
         production start-up of the new Profile 8 Fr. balloon catheter.

      Research and Development (R&D)

         R&D expenses, as a percentage of sales, amounted to 11.1% and 12.5% in
         the second quarter and first six months of fiscal 1999, respectively,
         compared to 12.0% and 13.1% last year.

         R&D expenses of $15.3 million declined slightly (less than 2%) in both
         the second quarter and first six months as lower development expenses
         in the Cardiac Assist division were partially offset by increases in
         the Patient Monitoring and Collagen Products divisions. Cardiac Assist
         division R&D expenses were higher last year due to development of the
         Profile 8 Fr. catheter and the System 98 balloon pump, two major new
         products currently being sold worldwide.


<PAGE>



      Selling, General & Administrative Expenses (SG&A)

         SG&A expenses, as a percentage of sales, were 42.1% and 44.1% in the
         second quarter and first six months of fiscal 1999, respectively,
         compared to 41.1% and 43.0% in the corresponding periods last year.

         SG&A expenses increased $2.3 million or 9% in the second quarter and
         $3.7 million or 7% in the first six months as a result of the expansion
         of the U.S. and European VasoSeal direct selling organization, higher
         selling and marketing expenses in the Patient Monitoring and Cardiac
         Assist businesses due to new product introduction marketing programs
         and additional headcount as a result of filling open sales
         representative and clinical education positions. Partially offsetting
         the above increases were reduced corporate expenses.

         The weaker U.S. dollar compared to major European currencies increased
         SG&A expenses by approximately $200 thousand in the second quarter and
         first six months of fiscal 1999.

      Interest Income and Expense

         The lower interest income in the second quarter and first six months
         was attributable to a reduction in the investment portfolio as $11.5
         million was used for the Company's common stock repurchase program.

      Other Income and Expense

         The Company enters into foreign exchange forward contracts to hedge a
         major portion of its foreign currency exposures, primarily related to
         certain receivables denominated in foreign currencies. The hedging has
         reduced the Company's exposure to fluctuations in foreign currencies.
         The net foreign exchange transaction gain or loss is reported in other
         income and expense. Foreign exchange forward contracts outstanding at
         December 31, 1998 totaled $1.9 million, all of which were in European
         currencies, with maturities that do not exceed 12 months.

      Net Earnings

         Net earnings in the second quarter of fiscal 1999 improved to $5.89
         million or $0.38 per diluted share compared to $5.65 million, or $0.34
         per diluted share. Net earnings for the first six months of fiscal 1999
         were $8.57 million or $0.55 per diluted share compared to $8.32 million
         or $0.50 per diluted share for the first six months last year. The
         earnings increases resulted primarily from strong growth of U.S.
         VasoSeal sales and lower corporate expenses.


<PAGE>



      Liquidity and Capital Resources

         Although working capital declined during the first six months of fiscal
         1999, the Company maintained its strong financial position. Working
         capital was $112.6 million at December 31, 1998 compared to $117.9
         million at June 30, 1998 and the current ratio was unchanged at 4.2:1.
         The decline in working capital was primarily attributable to using
         $11.5 million for the Company's common stock repurchase program.

         In the first six months cash was used to purchase $5.1 million of plant
         and equipment.

         In May 1996 the Company announced a stock repurchase program of up to
         $20 million to buy shares of its common stock from time to time subject
         to market conditions and other relevant factors affecting the Company.
         During the first quarter of fiscal 1999, the Company completed the May
         1996 repurchase program by purchasing $1.9 million of common stock
         remaining under this program. A second stock repurchase program for up
         to $20 million was approved by the board of directors on August 5, 1998
         and through December 31, 1998 the Company purchased $9.6 million of
         stock under this second repurchase program.

         Management believes that the Company's financial resources are
         sufficient to meet its projected cash requirements including the
         expenditures expected under the stock repurchase program.

         The moderate rate of current U.S. inflation has not significantly
         affected the Company.

Year 2000

      Many currently installed computer systems, software products and
      manufactured products that utilize microprocessors are coded to accept
      only two-digit entries in the date code field. These date code fields will
      need to accept four-digit entries to distinguish twenty-first century
      dates from twentieth century dates. This is commonly referred to as the
      "Year 2000 issue." The Company is aware of the Year 2000 issue and during
      fiscal 1998 commenced a program to identify, remediate, test and develop
      contingency plans for the Year 2000 issue (the "Y2K Program"), to be
      substantially completed by the fall of 1999.

      As of January 31, 1999, the results of the assessment being conducted
      under the Y2K Program were as follows:

      Computer Information Systems (Company CIS). Most of the Company CIS was
      found to be Year 2000 compliant. Several minor software programs that were
      not compliant were modified by December 31, 1998 by the software vendor or
      third party support vendor. Testing will continue throughout fiscal 1999
      to verify that software programs are year 2000 compliant.


<PAGE>



      Products.  It was determined that all currently marketed patient monitor
      and intra-aortic balloon pump products are Year 2000 compliant or are not
      affected because the product does not contain a date field in the
      software. A small number of patient monitor products that are no longer
      manufactured are not Year 2000 compliant. In these cases, the Company has
      plans to offer an upgrade to any customer requiring Year 2000 compliance
      for their monitor.

      Third Parties.  The Company solicited statements of compliance from its
      key outside vendors, manufacturers and suppliers with respect to their CIS
      and products. Approximately 63% of these parties responded and informed
      the Company that they are currently compliant or plan to be compliant by
      December 31, 1999. In the event that any of these parties are unable to
      certify that they will be Year 2000 compliant by early 1999, the Company
      will be reviewing its alternatives with respect to other vendors,
      manufacturers or suppliers (as applicable). The Company solicited
      statements of compliance, from its key customers at the end of October
      1998, with respect to their CIS. In the event that its key customers are
      unable to certify that they will be Year 2000 compliant by early 1999, the
      Company will be assessing the accounts receivable collection risk of such
      key customers.

      Costs.  The cost to modify the computer software programs used in the
      Company CIS is covered by existing service agreements with the software
      vendors. The assessments, testing and verification of all Company CIS and
      the Company's software and manufactured products was performed by existing
      staff. No significant outside resources were required. Despite the use of
      internal resources for the Y2K Program, there was no significant deferral
      of other Company CIS projects. The Company does not currently anticipate
      that the cost of the Y2K Program will be material to its financial
      condition or results of operations.

      The Year 2000 issue presents far-reaching implications, some of which
      cannot be anticipated with any degree of certainty. Satisfactorily
      addressing the Year 2000 issue is dependent on many factors, some of which
      are not completely within the Company's control, such as the availability
      of certain resources, third-party remediation plans and other factors.
      Based on the assessment that has been made under the Y2K Program, and
      other than as stated above, the Company has no other contingency plans in
      the event of any Year 2000 noncompliance and does not currently believe
      that any other contingency plans are necessary. In addition, management is
      not able to determine the effect of any Year 2000 noncompliance (including
      with respect to a "worst-case scenario") on the Company, and there can be
      no guarantee that any such noncompliance would not have an adverse effect
      on the Company's CIS, products, results of operations or financial
      condition.


<PAGE>



      Information Concerning Forward Looking Statements

         This Management's Discussion includes forward-looking statements that
         involve risks and uncertainties because of the possibility that market
         conditions may change, particularly as the result of competitive
         activity in the cardiac assist, vascular sealing device and other
         markets served by the Company, and because of the Company's dependence
         on its suppliers for certain patient monitoring products. Additional
         risks are the ability of the Company to successfully introduce and gain
         market acceptance for new products, continued demand for the Company's
         products generally, the rapid and significant changes that characterize
         the medical device and life science research industries and the ability
         to continue to respond to such technological changes, information
         provided to the Company by third parties concerning their year 2000
         readiness and because the timing of regulatory approvals is uncertain,
         as well as other risks detailed from time to time in documents filed by
         Datascope with the Securities and Exchange Commission.

Quantitative and Qualitative Disclosures About Market Risk

      The Company has only limited involvement with derivative financial
      instruments and does not use them for trading purposes. The Company enters
      into foreign currency forward exchange contracts to hedge foreign currency
      transactions (which are primarily related to certain receivables
      denominated in foreign currencies) on a continuing basis for periods
      consistent with its committed foreign currency exposures. The effect of
      this practice is to minimize the impact of foreign exchange rate movements
      on the Company's operating results. The Company's hedging activities do
      not subject the Company to exchange rate risk because gains and losses on
      these contracts offset losses and gains on the assets, liabilities and
      transactions being hedged. The net foreign exchange transaction gain or
      loss is reported in other income and expense.

      As of December 31, 1998, the Company had $1.9 million of foreign exchange
      forward contracts outstanding, all of which were in European currencies.
      The foreign exchange forward contracts generally have maturities that do
      not exceed 12 months and require the Company to exchange foreign
      currencies for U.S. dollars at maturity, at rates agreed to at inception
      of the contracts.


<PAGE>

                        Datascope Corp. and Subsidiaries
                           Consolidated Balance Sheets
                             (Dollars in thousands)

<TABLE>
<CAPTION>
                                                              Dec 31,          June 30,
                                                               1998             1998
                                                             ---------        ---------
<S>                                                          <C>              <C>
Assets                                                       (unaudited)         (a)
Current Assets:
  Cash and cash equivalents                                  $   6,400        $   3,364
  Short-term investments                                        24,790           46,314
  Accounts receivable, less allowance for doubtful
    accounts of $1,237 and $1,078                               58,765           55,248
  Inventories (Note 2)                                          48,451           40,246
  Prepaid expenses and other current assets                      9,663           10,036
                                                             ---------        ---------
      Total Current Assets                                     148,069          155,208

Property, Plant and Equipment, net of accumulated
  depreciation of $50,911 and $46,780                           55,522           50,946
Non-Current Marketable Securities                               31,152           34,371
Other Assets                                                    17,268           12,523
                                                             ---------        ---------
                                                             $ 252,011        $ 253,048
                                                             =========        =========
Liabilities and Stockholders' Equity
Current Liabilities:
  Accounts payable                                           $  12,450        $  14,378
  Accrued expenses                                              13,492           12,743
  Accrued compensation                                           7,132           10,190
  Taxes on income                                                2,433             --
                                                             ---------        ---------
      Total Current Liabilities                                 35,507           37,311

Other Liabilities                                               13,768           14,255
Stockholders' Equity (Notes 3, 4 and 5):
  Preferred stock, par value $1.00 per share:
    Authorized 5,000,000 shares; Issued, none                     --               --
  Common stock, par value $.01 per share:
    Authorized, 45,000,000 shares; Issued and
    outstanding, 16,549,787 and 16,394,387 shares                  165              164
  Additional paid-in capital                                    50,163           47,041
  Treasury stock at cost, 1,364,821 and 793,400 shares         (29,938)         (18,122)
  Retained earnings                                            186,076          177,509
  Accumulated other comprehensive income                        (3,730)          (5,110)
                                                             ---------        ---------
                                                               202,736          201,482
                                                             ---------        ---------
                                                             $ 252,011        $ 253,048
                                                             =========        =========
</TABLE>


                  (a) Derived from audited financial statements
                 See notes to consolidated financial statements


<PAGE>

                        Datascope Corp. and Subsidiaries
                       Statements of Consolidated Earnings
                    (In thousands, except per share amounts)
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                 Six Months Ended                Three Months Ended
                                                    December 31,                     December 31,
                                           --------------------------        --------------------------
                                             1998             1997              1998            1997
                                           ---------        ---------        ---------        ---------

<S>                                        <C>              <C>              <C>              <C>      
Net Sales                                  $ 122,400        $ 117,000        $  66,700        $  62,700
                                           ---------        ---------        ---------        ---------
Costs and Expenses:
  Cost of sales                               42,402           41,814           23,231           22,418
  Research and development
    expenses                                  15,263           15,376            7,429            7,551
  Selling, general and
    administrative expenses                   54,010           50,269           28,102           25,770
                                           ---------        ---------        ---------        ---------
                                             111,675          107,459           58,762           55,739
                                           ---------        ---------        ---------        ---------
Operating Earnings                            10,725            9,541            7,938            6,961
Other (Income) Expense:
  Interest income                             (1,869)          (2,561)            (797)          (1,272)
  Interest expense                                20               13               14                8
  Other, net                                     158               37              190               41
                                           ---------        ---------        ---------        ---------
                                              (1,691)          (2,511)            (593)          (1,223)
                                           ---------        ---------        ---------        ---------
Earnings Before Taxes on Income               12,416           12,052            8,531            8,184
Taxes on Income                                3,849            3,736            2,645            2,537
                                           ---------        ---------        ---------        ---------
Net Earnings                               $   8,567        $   8,316        $   5,886        $   5,647
                                           =========        =========        =========        =========

Earnings Per Share, Basic (Note 4)         $    0.56        $    0.52        $    0.39        $    0.35
                                           =========        =========        =========        =========
Weighted Average Number of
  Common and Common Equivalent
  Shares Outstanding, Basic                   15,296           16,005           15,174           15,978
                                           =========        =========        =========        =========

Earnings Per Share, Diluted (Note 4)       $    0.55        $    0.50        $    0.38        $    0.34
                                           =========        =========        =========        =========
Weighted Average Number of
  Common and Common Equivalent
  Shares Outstanding, Diluted                 15,688           16,504           15,550           16,559
                                           =========        =========        =========        =========
</TABLE>



                 See notes to consolidated financial statements


<PAGE>

                        Datascope Corp. and Subsidiaries
                      Statements of Consolidated Cash Flows
                             (Dollars in thousands)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                   Six Months Ended
                                                                      December 31
                                                               ------------------------
                                                                 1998            1997
                                                               --------        --------
<S>                                                            <C>             <C>    
Operating Activities:

     Net cash (used in) provided by operating activities       $ (4,859)       $ 12,303
                                                               --------        --------

Investing Activities:
     Capital expenditures                                        (5,105)         (3,905)
     Purchases of marketable securities                         (13,624)        (46,789)
     Maturities of marketable securities                         38,367          40,760
     Acquisition of Polyprobe, Inc. and Alpha Probe, Inc.          (450)            --
                                                               --------        --------
     Net cash provided by (used in) investing activities         19,188          (9,934)
                                                               --------        --------

Financing Activities:

     Treasury shares acquired under repurchase programs         (11,531)         (3,835)
     Exercise of stock options and other                            138           1,104
                                                               --------        --------

     Net cash used in financing activities                      (11,393)         (2,731)
                                                               --------        --------

     Effect of exchange rates on cash                               100            (652)
                                                               --------        --------

Increase (decrease) in cash and cash equivalents                  3,036          (1,014)
Cash and cash equivalents, beginning of period                    3,364           2,597
                                                               --------        --------

Cash and cash equivalents, end of period                       $  6,400        $  1,583
                                                               ========        ========

Supplemental Cash Flow Information
     Cash paid during the period for:
        Income taxes                                           $  1,331        $  1,995
                                                               --------        --------

     Non-cash transactions:
        Net transfers of inventory to fixed assets
           for use as demonstration equipment                  $  4,183        $  3,248
                                                               --------        --------

        Issuance of common stock for acquisition
           of Polyprobe, Inc. and Alpha Probe, Inc.            $  2,700             --
                                                               --------        --------
</TABLE>


                 See notes to consolidated financial statements


<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                                   (Unaudited)

1.  Basis of Presentation

The consolidated balance sheet as of December 31, 1998, the statements of
consolidated earnings for the three and six month periods ended December 31,
1998 and 1997 and the statements of cash flows for the six month periods ended
December 31, 1998 and 1997 have been prepared by the Company, without audit. In
the opinion of management, all adjustments (which include only normal recurring
adjustments) have been made that are necessary to present fairly the financial
position, results of operations and cash flows for all periods presented.

Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. It is suggested that the condensed consolidated
financial statements included herein be read in conjunction with the financial
statements and notes included in the Company's Annual Report on Form 10-K for
the fiscal year ended June 30, 1998. The results of operations for the period
ended December 31, 1998 are not necessarily indicative of a full year's
operations.

The presentation of certain prior year information has been reclassified to
conform with the current year presentation.

2.  Inventories

Inventories are stated at the lower of cost, determined on a first-in, first-out
basis, or market.                        
                                             
                                           (In thousands)
                              -----------------------------------------
                                  Dec 31,                  June 30,
                                   1998                     1998
                              ---------------          ---------------
         Materials              $      17,112           $       13,323
         Work in Process                6,129                    6,620
         Finished Goods                25,210                   20,303
                              ---------------          ---------------
                                $      48,451           $       40,246
                              ===============          ===============

3.  Stockholders' Equity

Changes in the components of stockholders' equity for the six months ended
December 31, 1998 were as follows:

                                                       (In thousands)
                                                       ---------------
       Net income                                       $        8,567
       Foreign currency translation adjustments                  1,380
       Common stock and additional paid-in
         capital effects of stock option activity                2,838
       Purchases under stock repurchase plans                  (11,531)
                                                       ---------------
       Total increase in stockholders' equity           $        1,254
                                                       ===============




<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                                   (Unaudited)

4.  Earnings Per Share

The Company adopted Financial Accounting Standard No. 128, "Earnings Per Share",
as required effective December 31, 1997. All prior earnings per share amounts
presented have been restated to conform with this statement. The reconciliation
of Basic Earnings Per Share to Diluted Earnings Per Share is as follows:

<TABLE>
<CAPTION>
----------------------------      -----------------------------------  ------------------------------------
For Three Months Ended                     December 31, 1998                   December 31, 1997
----------------------------      -----------------------------------  ------------------------------------
                                    Net                     Per Share    Net                      Per Share
Basic EPS                         Earnings     Shares        Amount    Earnings      Shares        Amount
---------                         --------     ------       ---------  --------      ------       ---------
<S>                               <C>          <C>          <C>        <C>           <C>          <C>
Earnings available to
   common shareholders            $5,886       15,174       $   0.39    $5,647       15,978       $   0.35

Diluted EPS
Options issued to employees         --            376            --       --            581            -- 
                                  ------       ------       --------    ------       ------       --------

Earnings available to
   common shareholders
   plus assumed conversions       $5,886       15,550       $   0.38    $5,647       16,559       $   0.34
                                  ======       ======       ========    ======       ======       ========


<CAPTION>
----------------------------      ----------------------------------  ------------------------------------
For Six Months Ended                      December 31, 1998                    December 31, 1997
----------------------------      ----------------------------------  ------------------------------------
                                    Net                    Per Share     Net                     Per Share
Basic EPS                         Earnings     Shares        Amount    Earnings      Shares        Amount
---------                         --------     ------      ---------   --------      ------      ---------
<S>                               <C>          <C>         <C>         <C>           <C>         <C>
Earnings available to
   common shareholders            $8,567       15,296       $   0.56    $8,316       16,005       $   0.52

Diluted EPS
Options issued to employees         --            392            --       --            499            -- 
                                  ------       ------       --------    ------       ------       --------

Earnings available to
   common shareholders
   plus assumed conversions       $8,567       15,688       $   0.55    $8,316       16,504       $   0.50
                                  ======       ======       ========    ======       ======       ========
</TABLE>


5.  Comprehensive Income

Effective July 1, 1998, the Company adopted Statement of Financial Accounting
Standards No. 130, "Reporting Comprehensive Income" (SFAS No. 130). This
statement requires the disclosure of comprehensive income and its components,
including net income, minimum pension liability adjustments, unrealized gains
and losses on available-for-sale securities and foreign currency translation
adjustments, in an annual financial statement displayed with the same prominence
as other annual financial statements. Interim reporting is required beginning
with the first quarter after adoption of the new standard and prior periods must
be restated.


<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                                   (Unaudited)

5.  Comprehensive Income (continued)

The Company's comprehensive income for the three and six months ended December
31, 1998 and 1997 was as follows:

                                               (In thousands)
                                 -------------------------------------------
                                  Six Months Ended        Three Months Ended
                                 12/31/98  12/31/97      12/31/98   12/31/97
                                 --------  --------      --------   --------
Net earnings                      $8,567    $8,316        $5,886     $5,647
Foreign currency translation       1,380    (1,036)            3       (422)
                                ---------  --------      --------  ---------
Total comprehensive income        $9,947    $7,280        $5,889     $5,225
                                =========  ========      ========  =========

The adoption of SFAS No. 130 had no effect on the Company's reported results of
operations or financial position.

6.  Acquisition of Polyprobe, Inc. and Alpha Probe, Inc.

On October 2, 1998, pursuant to merger agreements, the Company acquired 100% of
the outstanding common stock of Polyprobe, Inc. and Alpha Probe, Inc. The
purchase price for the acquisition of these companies was $3.2 million, paid
through the issuance of 125,141 shares of the Company's common stock and cash of
$450 thousand. Both acquisitions will be accounted for using the purchase method
of accounting. The excess of the purchase price over the fair value of the net
assets acquired, $3.1 million, has been allocated to goodwill and will be
amortized over a period of 10 years.


<PAGE>


Part II:

    Item 6.   Exhibits and Reports on Form 8-K

              a.  Exhibits

                  none

              b.  Reports on Form 8-K. No reports on Form 8-K have been filed
                  during the quarter for which this report is filed.


<PAGE>

                                                                       Form 10-Q

SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      Registrant has duly caused this Report to be signed on its behalf by the
      undersigned, thereunto duly authorized.

                                 DATASCOPE CORP.
                                 Registrant

                                 By: /s/ Lawrence Saper
                                     ----------------------------------
                                     Lawrence Saper
                                     Chairman of the Board and
                                     Chief Executive Officer

                                 By: /s/ Leonard S. Goodman
                                     ----------------------------------
                                     Leonard S. Goodman
                                     Vice President and
                                     Chief Financial Officer

Dated:  February 12, 1999